Short description
Gyroscope Therapeutics is a clinical-stage gene therapy company focused on developing therapies and treating diseases of the eye.
Description
Gyroscope is a clinical-stage gene therapy company focused on developing therapies and treating diseases of the eye.
The company explores the convergence of advancements made in the understanding of the complement system’s impact on eye disease, the genetic basis of Age-related Macular Degeneration (AMD), and gene therapy as a mode of treatment delivery. Its lead investigational gene therapy, GT005, is a one-time therapy delivered under the retina. GT005 is designed to restore balance to an overactive complement system by increasing the production of the Complement Factor I protein. GT005 is currently being evaluated in a Phase I/II clinical trial called FOCUS and Phase II clinical trials called EXPLORE and HORIZON.
Andrew Lotery, David Kavanagh, and Peter Lachmann co-founded Gyroscope Therapeutics in Stevenage, Herefordshire in 2016.
Last funding
Noaccess
Sign in for full access
Total funding
$$3123123
Sign in for full access
Location
Stevenage, Herefordshire, United Kingdom, Europe
Founded on
January 1, 2016
Exited on
December 22, 2021
Non-profit?
No
Acquired?
No
Employees count
101-250
Revenue range
$7890 - 12340
Sign in for full access
Investors
No Way, Blurry Noaccess, No Way, Blurry Noaccess, Cannot Access, Noaccess, Nopepepe, Noway Youcantaccess
Sign in for full access
Founders
Andrew Lotery, David Kavanagh, Peter Lachmann, Tim Funnell